홈 > 시장보고서 > 의약품

시장보고서

상품코드

2013140

항섬유소용해제 시장 : 유형별, 적응증별, 최종 용도별, 제형별, 국가별, 지역별 - 세계 산업 분석, 시장 규모, 시장 점유율, 예측(2026-2033년)

Antifibrinolytic Drugs Market, By Type, By Indication, By End Use, By Form, By Country, and By Region -Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033

발행일: 2026년 04월 | 리서치사: 구분자

AnalystView Market Insights | 페이지 정보: 영문 288 Pages | 배송안내 : 2-3일 (영업일 기준)

가격

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 3,250

￦ 4,918,000

PDF (5 User License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,650

￦ 7,037,000

PDF & Excel (Enterprise User License)

PDF & Excel 보고서를 동일 기업 내 모든 사용자가 사용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,650

￦ 8,551,000

※ 부가세 별도

한글목차

영문목차

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

항섬유소용해제 시장 규모는 2025년에 420억 6,187만 달러로 평가되며, 2026-2033년에 CAGR 7.99%로 확대할 것으로 전망되고 있습니다.

항응고제는 혈액이 응고되는 것을 돕고 응고된 혈액 덩어리가 빠르게 분해되는 것을 방지하는 의약품을 말합니다. 이들은 혈전을 안정화시키는 플라스미노겐의 활성화를 억제하여 작용합니다. 이 약물은 대량 출혈, 혈관종, 월경과다를 치료하는 데 사용됩니다. 또한 수술 중이나 수술 후 출혈을 조절하는 데에도 사용됩니다. 일반적인 항선용제에는 트라넥삼산, 아프로티닌, 아미노카프론산, 세린 프로테아제 억제제 등이 있습니다. 이들은 일반적으로 구강, 비강, 소화관 및 자궁 출혈 관리에 사용됩니다. 그 결과, 병원, 진료소 및 수술 센터에서 널리 사용되고 있습니다.

항선 용해제 시장은 피브린의 분해를 억제하고 혈전의 안정성을 유지하여 혈액 응고를 돕고 과도한 출혈을 방지하는 의약품으로 구성되어 있습니다. 이 시장에는 출혈, 월경과다, 혈관 질환의 증가, 수술 및 외상 치료에서 효과적인 출혈 관리에 대한 수요 증가가 포함됩니다. 예를 들어 2025년 2월 현재 미국 정부의 보고에 따르면 100명의 여성 중 약 10명(약 10%)이 월경과다를 경험하고 있으며, 이는 평소보다 출혈이 심하거나 장기간 지속되어 일상 생활에 영향을 미칠 수 있습니다. 일반적으로 생리가 5-7일 이상 지속되면 월경이 장기화되었다고 간주하며, 주기당 출혈량이 정기적으로 80mL를 초과하는 경우 철분 결핍이나 빈혈을 유발할 수 있습니다. 이 수치는 전 세계 여성 건강에서 월경과다증의 유병률과 영향을 강조하며, 월경과다증이 월경 건강에서 드문 현상이 아니라 흔한 현상임을 보여줍니다. 이는 환자의 예후를 관리하고 개선하기 위한 효과적인 항선용해 치료법과 인식 개선 활동이 매우 필요함을 강조하고 있습니다.

항선 용매 시장 - 시장 역학

제네릭 항선용해제의 접근성 향상으로 시장 수요를 견인

제네릭 항선용해제, 특히 트라넥삼산(Tranexamic acid)의 접근성이 높아짐에 따라 병원, 수술센터, 응급의료기관에서 보다 저렴한 가격으로 치료제를 제공하고 널리 사용할 수 있게 됨으로써 시장 성장에 기여하고 있습니다. 저렴한 제네릭 의약품은 비용을 절감하고 중저소득 지역의 더 많은 사람들이 이용할 수 있도록 합니다. 여러 제조업체의 생산량 증가는 안정적인 공급을 보장하고, 특히 외상 및 산부인과 의료 분야의 국가 의료 프로그램을 지원합니다. 예를 들어 2024년 6월 아베나시는 FDA 승인을 받은 '트라넥삼산 주사액(USP)'을 미국에서 출시할 것이라고 발표했습니다. 사이클로카프론의 치료용 제네릭 의약품입니다. 이 제품은 혈우병 환자의 출혈을 예방 또는 감소시키고, 발치 중 및 발치 후 보철 요법을 최소화하기 위해 단기간 사용을 목적으로 도입되었습니다. 이러한 추세는 전 세계에서 환자 접근성 향상과 출혈 관리에 있으며, 제네릭 의약품의 역할이 확대되고 있음을 보여줍니다.

항선 용매 시장 - 세분화 분석:

세계의 항선 용해제 시장은 유형, 적응증, 최종 용도, 제형 및 지역을 기준으로 세분화됩니다.

유형별로는 트라넥삼산이 다양한 병태생리에서 과도한 출혈을 억제하는 데 널리 사용되어 큰 비중을 차지하고 있습니다. 아미노카프론산, 아프로티닌, 피브리노겐과 같은 항선 용해제는 수술, 외상, 부인과 시술에서 출혈을 효과적으로 관리하여 전 세계에서 채택이 확대되고 있습니다. 의료진과 환자들 사이에서 이러한 약물의 장점에 대한 인식이 높아지면서 다른 치료 옵션보다 우선순위를 두는 경향이 높아져 시장 수요가 증가하고 있습니다. 예를 들어 NHS Confederation의 보고서에 따르면 심한 생리통, 월경과다, 자궁내막증, 자궁근종, 난소낭종으로 인한 결근으로 인한 경제적 비용은 영국에서만 연간 약 147억 달러에 달하는 것으로 추정됩니다. 또한 약 6만 명의 여성이 갱년기 관련 증상으로 인해 일을 하지 못하고 있으며, 이로 인해 연간 약 20억 1,000만 달러의 경제적 손실이 발생한다고 합니다. 산부인과 서비스에 여성 1인당 1.34달러를 추가로 투자하면 14.74달러의 매출을 얻을 수 있으며, 이는 큰 경제적, 사회적 이익을 가져다 줄 수 있다는 것을 보여줍니다. 이러한 요인들이 종합적으로 부인과 의료에서 항선용해제의 중요성 증가와 시장 잠재력을 강조하고 있습니다.

항선용해제 시장은 적응증에 따라 부인과, 유전성 혈관성 부종, 선용성 반응 검사, 외과수술, 기타로 분류되며, 각각 특정 의료 수요에 대응하고 있습니다. 부인과 및 외과수술은 대량 출혈 및 출혈 관리의 역할로 인해 항선 용해제의 주요 영역이 되었으며, 유전성 혈관 부종 및 선천성 혈관 부종 및 선천성 용해 반응 검사는 전문적인 환자 치료 요구에 대응하고 있습니다. 예를 들어 2025년 12월 기준 영국 혈우병센터 의사협회(UKHCDO) 등록부에 등록된 영국 전역의 출혈성 질환 환자는 4만 2,691명이며, 이 중 9,999명은 혈우병 A(및 보균자), 2,237명은 혈우병 B(및 보균자), 1만 2,825명은 폰 빌레브란트병이었습니다. 2024년 4월부터 2025년 3월까지의 이 수치는 지난 수년간 비해 증가했으며, 각 센터의 진단 및 데이터 수집이 지속적으로 개선되고 있음을 반영합니다. 이 보고서는 영국의 혈우병 의료 서비스에서 다양한 출혈성 질환을 가진 개인에 대한 광범위한 치료 노력과 데이터 보고를 보여줍니다.

항선 용매 시장 - 지역별 인사이트

지정학적 요인으로 인해 무역 혼란과 공급망 문제가 발생하여 항선 용해제 시장에 영향을 미치고, 중요한 원자재에 대한 접근을 제한하고 필수 의약품의 생산과 유통을 방해할 수 있습니다.

북미는 수술 및 외상 치료에서 효과적인 출혈 제어 솔루션의 사용 확대에 따라 시장에서 큰 비중을 차지하고 있습니다. 수술의 대중화와 더불어 고령화 사회로 인해 잦은 수술을 필요로 하는 고령화 사회로 인해 과도한 출혈을 방지하는 약품에 대한 수요가 증가하고 있습니다. 예를 들어 ISAPS(국제미용외과학회)의 보고에 따르면 2023년 전 세계에서 약 3,490만 건의 미용 시술이 이루어졌으며, 이는 2022년에 비해 3.4% 증가한 수치입니다. 이 중 약 1,580만 건이 수술적 시술, 1,910만 건이 비수술적 시술로 미용치료가 전 세계에서 널리 보급되고 있음을 알 수 있습니다. 안면 및 두부 수술은 650만 건을 넘어 전년 대비 19.6% 증가했습니다. 한편, 보툴리눔 톡신 등 주사 치료는 약 890만 건에 달했으며, 외과적 및 비외과적 미용 치료 모두에서 강력한 성장세를 보였다. 이러한 추세는 전 세계에서 전문 의약품 및 의료 솔루션에 대한 수요를 견인하는 데 있으며, 의료 시술의 역할이 확대되고 있음을 보여줍니다.

아시아태평양에서는 수술 및 외상 치료에서 혈액 관리에 대한 인식이 높아짐에 따라 상당한 성장이 예상됩니다. 중국, 인도 등의 국가에서는 의료 인프라의 확충과 고급 의료시설에 대한 접근성 향상으로 수술 건수의 증가가 예상됩니다. 예를 들어 2024년 중국의 의료 시스템은 계속 확장되어 전국 의료 및 보건 기관의 총 수가 100만 개가 넘어 의료 인프라의 꾸준한 성장을 반영합니다. 국가위생건강위원회 보고서에 따르면 중국에서는 연간 90억 건 이상의 의료 및 건강 서비스 방문이 기록되어 의료 수요의 증가가 두드러지고 있습니다. 또한 면허를 취득한 의사 보조원 수는 470만 명을 넘어섰고, 등록 간호사는 560만 명을 넘어섰으며, 의료 종사자의 지속적인 증가를 보여주고 있습니다. 이러한 추세는 지역 전체에서 항선 용해제의 채택 확대를 종합적으로 촉진하고 있습니다.

한국 발포 크리머 시장 - 국가별 인사이트

각 국가 중 중국에서는 수술 건수의 증가와 산모 건강 프로그램의 확대로 인해 채용 패턴이 눈에 띄게 성장하고 있습니다. 중국에서는 입원 수술 건수가 상당한 수준에 이르렀고, 항선 용해제에 대한 강한 수요가 부각되고 있습니다. 또한 이 지역에서는 혈우병과 같은 만성 혈액 질환의 유병률 증가로 인해 효과적인 혈액 관리 솔루션에 대한 수요가 증가할 것으로 예상됩니다. 예를 들어 국가위생건강위원회(NHC)의 데이터에 따르면 지난 10년간 중국은 주요 만성질환으로 인한 조기 사망률을 약 19% 감소시켜 2015년 18.5%에서 2023년 15%로 낮췄다고 합니다. 만성질환은 여전히 연간 총 사망자 수의 80% 이상을 차지하고 있으며, 그 건강 부담이 얼마나 큰지 알 수 있습니다. 이에 대응하기 위해 중국은 488개의 만성질환 예방 국가 모델 지구를 설립하여 현급 지역의 약 17.1%를 커버하는 동시에 검진 및 건강 증진 노력을 확대하고 있습니다. 이러한 의료 환경의 변화로 항선 용해제를 포함한 첨단 출혈 관리 요법에 대한 수요는 지속될 것으로 예상됩니다.

Antifibrinolytic drugs refer to medicines that help the blood form clots and stop them from breaking down too quickly. They act by blocking the activation of plasminogen, which keeps clots stable. These drugs are used to treat heavy bleeding, vascular tumors, and heavy menstrual bleeding. They are also used to control bleeding during or after surgeries. Common antifibrinolytic drugs include tranexamic acid, aprotinin, aminocaproic acid, and serine protease inhibitors. They are commonly used to manage bleeding in the mouth, nose, digestive tract, and uterus. As a result, they are widely used in hospitals, clinics, and surgical centers.

The Antifibrinolytic Drugs market consists of medicines that help the blood form clots and prevent excessive bleeding, reducing the breakdown of fibrin and maintaining clot stability. This market includes increasing cases of hemorrhages, heavy menstrual bleeding, and vascular disorders, along with the growing demand for effective bleeding management during surgeries and trauma care. For instance, in Feb 2025, according to the US govt., about 10 out of every 100 women (≈ 10%) experience heavy menstrual periods, where bleeding is more intense or prolonged than normal and can affect daily life. A period lasting longer than five to seven days is generally considered prolonged, and blood loss regularly exceeding 80 mL per cycle may lead to iron deficiency and anemia. These figures highlight the prevalence and impact of heavy menstrual bleeding on women's health globally, showing that such symptoms are common rather than rare phenomena in menstrual health. This underscores the critical need for effective antifibrinolytic therapies and awareness to manage and improve patient outcomes.

Antifibrinolytic Drugs Market- Market Dynamics

Increasing Accessibility Of Generic Antifibrinolytic Medications To Propel Market Demand

Increasing accessibility of generic antifibrinolytic medications, especially tranexamic acid, is helping the market grow by making treatments more affordable and widely available in hospitals, surgical centers, and emergency care. Cheaper generics lower costs, allowing more people in low- and middle-income areas to access them. Greater production from multiple manufacturers ensures a steady supply and supports national healthcare programs, particularly in trauma and obstetric care. For instance, in June 2024, Avenacy announced the U.S. launch of its FDA-approved Tranexamic Acid Injection, USP, a therapeutic generic to Cyklokapron. The product was introduced for short-term use in hemophilia patients to prevent or reduce bleeding and minimize replacement therapy during and after tooth extraction. These developments highlight the growing role of generics in improving patient access and bleeding management worldwide.

Antifibrinolytic Drugs Market- Segmentation Analysis:

The Global Antifibrinolytic Drugs Market is segmented on the basis of Type, Indication, End Use, Form, and Region.

Under Type, Tranexamic Acid held a significant share due to its widespread use in controlling excessive bleeding across various medical conditions. Antifibrinolytic drugs such as aminocaproic acid, aprotinin, and fibrinogen effectively manage bleeding in surgeries, trauma, and gynecological procedures, supporting their growing adoption globally. Increasing awareness among healthcare providers and patients about the benefits of these drugs encourages their preference over other treatment options, fueling market demand. For instance, the NHS Confederation Org report shows that the economic cost of absenteeism due to severe period pain, heavy periods, endometriosis, fibroids, and ovarian cysts is estimated at nearly $14.7 billion per year in England alone. It also highlights that approximately 60,000 women are not in employment due to menopause-related symptoms, resulting in an economic impact of around $2.01 billion per annum. Investing an extra $1.34 per woman in obstetrics and gynecology services could yield an $14.74 return, highlighting significant economic and social benefits. These factors collectively underscore the growing importance and market potential of antifibrinolytic drugs in gynecological care.

The antifibrinolytic drugs market is segmented by indication into gynecology, hereditary angioedema, fibrinolytic testing, surgeries, and others, each serving specific medical needs. Gynecology and surgeries are key areas for antifibrinolytic drugs due to their role in managing heavy bleeding and blood loss, while hereditary angioedema and fibrinolytic testing address specialized patient care needs. For instance, in Dec. 2025, the UK Haemophilia Centre Doctors' Organisation (UKHCDO) registry recorded 42,691 people registered with a bleeding disorder across the UK, including 9,999 with hemophilia A (and carriers), 2,237 with hemophilia B (and carriers), and 12,825 with von Willebrand disease. From April 2024 to March 2025, these figures represent an increase compared with previous years, reflecting ongoing improvements in diagnosis and data capture across centers. centers. The report shows the extensive care engagement and data reporting for individuals with various bleeding disorders across UK hemophilia services.

Antifibrinolytic Drugs Market- Geographical Insights

Geopolitical factors impact the antifibrinolytic drugs market by causing trade disruptions and supply chain challenges, which can limit access to critical raw materials and hinder the production and distribution of essential medications.

North America accounted for a significant portion of the market due to the growing use of effective bleeding control solutions in surgical and trauma care. The prevalence of surgical procedures, along with an aging population requiring frequent surgeries, has increased the need for drugs that help prevent excessive blood loss. For instance, in 2023, the ISAPS Org reported that nearly 34.9 million cosmetic procedures were performed worldwide, a 3.4% increase compared with 2022. Of these, about 15.8 million were surgical and 19.1 million were non-surgical procedures, illustrating broad uptake of aesthetic treatments globally. Face and head procedures exceeded 6.5 million, with a 19.6 % increase from the previous year, while injectable treatments like botulinum toxin reached about 8.9 million, showing strong growth in both surgical and non-surgical aesthetic care. These trends highlight the expanding role of medical procedures in driving demand for specialized drugs and healthcare solutions globally.

Asia Pacific is anticipated to experience significant growth due to increasing awareness of blood management in surgeries and trauma care. Countries such as China and India are expected to see a rising number of surgical procedures as healthcare infrastructure expands and access to advanced medical facilities improves. For instance, in 2024, China's healthcare system continued to expand, with the total number of medical and health institutions exceeding 1 million nationwide, reflecting steady growth in healthcare infrastructure. According to the National Health Commission, the country recorded over 9 billion medical and health service visits annually, highlighting rising healthcare demand. Additionally, the number of licensed assistant physicians exceeded 4.7 million, and registered nurses surpassed 5.6 million, indicating ongoing growth in the healthcare workforce. These developments collectively support the expanding adoption of antifibrinolytic drugs across the region.

South Korea Foaming Creamer Market- Country Insights

Among all countries, China is witnessing notable growth in adoption patterns due to rising surgical volumes and expanding maternal health programs. In China, the number of inpatient surgeries has reached a substantial level, highlighting strong demand for antifibrinolytic solutions. The region is also expected to benefit from the rising incidence of chronic blood disorders, such as hemophilia, which increases the need for effective blood management solutions. For instance, over the past decade, according to the NHC Gov.

China has reduced the premature death rate from major chronic diseases by nearly 19%, declining from 18.5% in 2015 to 15% in 2023. Chronic diseases still account for over 80% of total deaths annually, highlighting their significant health burden. To address this, the country has established 488 national demonstration areas for chronic disease prevention, covering about 17.1% of county-level regions, alongside expanded screening and health promotion initiatives. This evolving healthcare landscape is expected to sustain the demand for advanced bleeding management therapies, including antifibrinolytic drugs.

Antifibrinolytic Drugs Market- Competitive Landscape:

The major players in the antifibrinolytic drugs market focus on innovation and strategic initiatives to strengthen their market position. They invest in research and development to enhance formulations and improve outcomes for patients with bleeding disorders. Collaborations with hospitals and clinics help boost clinical adoption and product credibility. These companies are also expanding into emerging markets, with key players including ACIC Pharmaceuticals Inc., Akorn Inc., Aurobindo Pharma Limited, Novartis AG, Pfizer Inc., and Vitruvias Therapeutics Inc. In January 2023, Pfizer entered into a partnership with a biotechnology firm to develop advanced antifibrinolytic drug formulations aimed at reducing postoperative bleeding complications. This collaboration supports growth in the antifibrinolytic drugs market by advancing therapeutic options for surgical and trauma patients, addressing the increased need for enhanced treatment solutions in critical care settings.

Recent Developments:

In January 2025 - Novartis AG entered into an agreement to acquire Anthos Therapeutics for approximately $925 million, strengthening its late-stage cardiovascular and hemostasis pipeline.

In September 2023 - ACIC Pharmaceuticals Inc., in collaboration with Methapharm, Inc. and Bioindustria Laboratorio Italiano Medicinali S.p.A., filed FDA registrations for tranexamic acid, advancing its commercialization in the U.S. antifibrinolytic market.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Pfizer Inc.
Novartis AG
Sanofi SA
Takeda Pharmaceutical Company Limited
Viatris Inc.
Bayer AG
Aurobindo Pharma Limited
Ferring Pharmaceuticals
Zydus Lifesciences Limited
ACIC Pharmaceuticals Inc.
Johnson & Johnson (Ethicon - surgical bleeding control)
Octapharma AG
Apotex Inc.
Aspen Pharmacare Holdings Limited
Cipla Limited
Others

GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET, BY TYPE- MARKET ANALYSIS, 2020 - 2033

Tranexamic Acid
Aminocaproic Acid
Aprotinin
Lysteda
RiaSTAP
Fibrinogen
Trasylol
Amicor
Others

GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET, BY INDICATION- MARKET ANALYSIS, 2020 - 2033

Surgeries
Gynaecology
Hereditary Angioedema
Fibrinolytic Response Testing
Others

GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET, BY END USE- MARKET ANALYSIS, 2020 - 2033

Clinics
Hospitals
Ambulatory Surgery Centres
Health Care Specialty Processes
Others

GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET, BY FORM- MARKET ANALYSIS, 2020 - 2033

Injectable
Oral
Others

GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Antifibrinolytic Drugs Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Antifibrinolytic Drugs Market Snippet by Type
- 2.1.2. Antifibrinolytic Drugs Market Snippet by Indication
- 2.1.3. Antifibrinolytic Drugs Market Snippet by End Use
- 2.1.4. Antifibrinolytic Drugs Market Snippet by Form
- 2.1.5. Antifibrinolytic Drugs Market Snippet by Country
- 2.1.6. Antifibrinolytic Drugs Market Snippet by Region
2.2. Competitive Insights

3. Antifibrinolytic Drugs Key Market Trends

3.1. Antifibrinolytic Drugs Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Antifibrinolytic Drugs Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Antifibrinolytic Drugs Market Opportunities
3.4. Antifibrinolytic Drugs Market Future Trends

4. Antifibrinolytic Drugs Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Antifibrinolytic Drugs Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Antifibrinolytic Drugs Market Landscape

6.1. Antifibrinolytic Drugs Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Antifibrinolytic Drugs Market - By Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Type, 2025 & 2033 (%)
- 7.1.2. Tranexamic Acid
- 7.1.3. Aminocaproic Acid
- 7.1.4. Aprotinin
- 7.1.5. Lysteda
- 7.1.6. RiaSTAP
- 7.1.7. Fibrinogen
- 7.1.8. Trasylol
- 7.1.9. Amicor
- 7.1.10. Others

8. Antifibrinolytic Drugs Market - By Indication

8.1. Overview
- 8.1.1. Segment Share Analysis, By Indication, 2025 & 2033 (%)
- 8.1.2. Surgeries
- 8.1.3. Gynaecology
- 8.1.4. Hereditary Angioedema
- 8.1.5. Fibrinolytic Response Testing
- 8.1.6. Others

9. Antifibrinolytic Drugs Market - By End Use

9.1. Overview
- 9.1.1. Segment Share Analysis, By End Use, 2025 & 2033 (%)
- 9.1.2. Clinics
- 9.1.3. Hospitals
- 9.1.4. Ambulatory Surgery Centres
- 9.1.5. Health Care Specialty Processes

10. Antifibrinolytic Drugs Market - By Form

10.1. Overview
- 10.1.1. Segment Share Analysis, By Indication, 2025 & 2033 (%)
- 10.1.2. Injectable
- 10.1.3. Oral

11. Antifibrinolytic Drugs Market - By Geography

11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
11.2. North America
- 11.2.1. Overview
- 11.2.2. Antifibrinolytic Drugs Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
- 11.2.8. U.S.
  - 11.2.8.1. Overview
  - 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.2.8.3. U.S. Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.2.8.4. U.S. Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 11.2.8.5. U.S. Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  - 11.2.8.6. U.S. Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
- 11.2.9. Canada
  - 11.2.9.1. Overview
  - 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.2.9.3. Canada Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.2.9.4. Canada Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 11.2.9.5. Canada Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  - 11.2.9.6. Canada Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.3. Europe
- 11.3.1. Overview
- 11.3.2. Antifibrinolytic Drugs Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
- 11.3.8. Germany
  - 11.3.8.1. Overview
  - 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.8.3. Germany Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.3.8.4. Germany Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 11.3.8.5. Germany Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  - 11.3.8.6. Germany Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
- 11.3.9. UK
  - 11.3.9.1. Overview
  - 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.9.3. UK Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.3.9.4. UK Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 11.3.9.5. UK Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  - 11.3.9.6. UK Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
- 11.3.10. France
  - 11.3.10.1. Overview
  - 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.10.3. France Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.3.10.4. France Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 11.3.10.5. France Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  - 11.3.10.6. France Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
- 11.3.11. Italy
  - 11.3.11.1. Overview
  - 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.11.3. Italy Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.3.11.4. Italy Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 11.3.11.5. Italy Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  - 11.3.11.6. Italy Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
- 11.3.12. Spain
  - 11.3.12.1. Overview
  - 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.12.3. Spain Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.3.12.4. Spain Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 11.3.12.5. Spain Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  - 11.3.12.6. Spain Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
- 11.3.13. The Netherlands
  - 11.3.13.1. Overview
  - 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.13.3. The Netherlands Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.3.13.4. The Netherlands Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 11.3.13.5. The Netherlands Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  - 11.3.13.6. The Netherlands Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
- 11.3.14. Sweden
  - 11.3.14.1. Overview
  - 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.14.3. Sweden Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.3.14.4. Sweden Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 11.3.14.5. Sweden Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  - 11.3.14.6. Sweden Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
- 11.3.15. Russia
  - 11.3.15.1. Overview
  - 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.15.3. Russia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.3.15.4. Russia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 11.3.15.5. Russia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  - 11.3.15.6. Russia Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
- 11.3.16. Poland
  - 11.3.16.1. Overview
  - 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.16.3. Poland Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.3.16.4. Poland Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 11.3.16.5. Poland Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  - 11.3.16.6. Poland Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
- 11.3.17. Rest of Europe
  - 11.3.17.1. Overview
  - 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.3.17.3. Rest of the Europe Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.3.17.4. Rest of the Europe Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 11.3.17.5. Rest of the Europe Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  - 11.3.17.6. Rest of the Europe Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Antifibrinolytic Drugs Key Manufacturers in Asia Pacific
- 11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.4.4. APAC Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 11.4.5. APAC Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
- 11.4.6. APAC Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.4.7. APAC Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
- 11.4.8. China
  - 11.4.8.1. Overview
  - 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.8.3. China Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.4.8.4. China Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 11.4.8.5. China Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  - 11.4.8.6. China Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
- 11.4.9. India
  - 11.4.9.1. Overview
  - 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.9.3. India Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.4.9.4. India Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 11.4.9.5. India Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  - 11.4.9.6. India Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
- 11.4.10. Japan
  - 11.4.10.1. Overview
  - 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.10.3. Japan Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.4.10.4. Japan Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 11.4.10.5. Japan Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  - 11.4.10.6. Japan Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
- 11.4.11. South Korea
  - 11.4.11.1. Overview
  - 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.11.3. South Korea Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.4.11.4. South Korea Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 11.4.11.5. South Korea Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  - 11.4.11.6. South Korea Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
- 11.4.12. Australia
  - 11.4.12.1. Overview
  - 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.12.3. Australia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.4.12.4. Australia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 11.4.12.5. Australia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  - 11.4.12.6. Australia Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
- 11.4.13. Indonesia
  - 11.4.13.1. Overview
  - 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.13.3. Indonesia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.4.13.4. Indonesia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 11.4.13.5. Indonesia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  - 11.4.13.6. Indonesia Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
- 11.4.14. Thailand
  - 11.4.14.1. Overview
  - 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.14.3. Thailand Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.4.14.4. Thailand Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 11.4.14.5. Thailand Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  - 11.4.14.6. Thailand Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
- 11.4.15. Philippines
  - 11.4.15.1. Overview
  - 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.15.3. Philippines Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.4.15.4. Philippines Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 11.4.15.5. Philippines Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  - 11.4.15.6. Philippines Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
- 11.4.16. Rest of APAC
  - 11.4.16.1. Overview
  - 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.4.16.3. Rest of APAC Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.4.16.4. Rest of APAC Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 11.4.16.5. Rest of APAC Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  - 11.4.16.6. Rest of APAC Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.5. Latin America (LATAM)
- 11.5.1. Overview
- 11.5.2. Antifibrinolytic Drugs Key Manufacturers in Latin America
- 11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.5.4. LATAM Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 11.5.5. LATAM Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
- 11.5.6. LATAM Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.5.7. LATAM Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
- 11.5.8. Brazil
  - 11.5.8.1. Overview
  - 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.5.8.3. Brazil Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.5.8.4. Brazil Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 11.5.8.5. Brazil Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  - 11.5.8.6. Brazil Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
- 11.5.9. Mexico
  - 11.5.9.1. Overview
  - 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.5.9.3. Mexico Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.5.9.4. Mexico Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 11.5.9.5. Mexico Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  - 11.5.9.6. Mexico Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
- 11.5.10. Argentina
  - 11.5.10.1. Overview
  - 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.5.10.3. Argentina Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.5.10.4. Argentina Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 11.5.10.5. Argentina Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  - 11.5.10.6. Argentina Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
- 11.5.11. Colombia
  - 11.5.11.1. Overview
  - 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.5.11.3. Colombia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.5.11.4. Colombia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 11.5.11.5. Colombia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  - 11.5.11.6. Colombia Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
- 11.5.12. Rest of LATAM
  - 11.5.12.1. Overview
  - 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.5.12.3. Rest of LATAM Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.5.12.4. Rest of LATAM Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 11.5.12.5. Rest of LATAM Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  - 11.5.12.6. Rest of LATAM Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
11.6. Middle East and Africa (MEA)
- 11.6.1. Overview
- 11.6.2. Antifibrinolytic Drugs Key Manufacturers in Middle East and Africa
- 11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 11.6.4. MEA Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
- 11.6.5. MEA Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
- 11.6.6. MEA Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
- 11.6.7. MEA Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
- 11.6.8. Saudi Arabia
  - 11.6.8.1. Overview
  - 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.8.3. Saudi Arabia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.6.8.4. Saudi Arabia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 11.6.8.5. Saudi Arabia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  - 11.6.8.6. Saudi Arabia Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
- 11.6.9. United Arab Emirates
  - 11.6.9.1. Overview
  - 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.9.3. United Arab Emirates Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.6.9.4. United Arab Emirates Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 11.6.9.5. United Arab Emirates Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  - 11.6.9.6. United Arab Emirates Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
- 11.6.10. Israel
  - 11.6.10.1. Overview
  - 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.10.3. Israel Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.6.10.4. Israel Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 11.6.10.5. Israel Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  - 11.6.10.6. Israel Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
- 11.6.11. Turkey
  - 11.6.11.1. Overview
  - 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.11.3. Turkey Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.6.11.4. Turkey Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 11.6.11.5. Turkey Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  - 11.6.11.6. Turkey Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
- 11.6.12. Algeria
  - 11.6.12.1. Overview
  - 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.12.3. Algeria Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.6.12.4. Algeria Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 11.6.12.5. Algeria Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  - 11.6.12.6. Algeria Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
- 11.6.13. Egypt
  - 11.6.13.1. Overview
  - 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.13.3. Egypt Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.6.13.4. Egypt Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 11.6.13.5. Egypt Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  - 11.6.13.6. Egypt Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)
- 11.6.14. Rest of MEA
  - 11.6.14.1. Overview
  - 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 11.6.14.3. Rest of MEA Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  - 11.6.14.4. Rest of MEA Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 11.6.14.5. Rest of MEA Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
  - 11.6.14.6. Rest of MEA Market Size and Forecast, By Form, 2020 - 2033 (US$ Million)

12. Key Vendor Analysis- Antifibrinolytic Drugs Industry

12.1. Competitive Benchmarking
- 12.1.1. Competitive Dashboard
- 12.1.2. Competitive Positioning
12.2. Company Profiles
- 12.2.1. Pfizer Inc.
- 12.2.2. Novartis AG
- 12.2.3. Sanofi SA
- 12.2.4. Takeda Pharmaceutical Company Limited
- 12.2.5. Viatris Inc.
- 12.2.6. Bayer AG
- 12.2.7. Aurobindo Pharma Limited
- 12.2.8. Ferring Pharmaceuticals
- 12.2.9. Zydus Lifesciences Limited
- 12.2.10. ACIC Pharmaceuticals Inc.
- 12.2.11. Johnson & Johnson (Ethicon - surgical bleeding control)
- 12.2.12. Octapharma AG
- 12.2.13. Apotex Inc.
- 12.2.14. Aspen Pharmacare Holdings Limited
- 12.2.15. Cipla Limited
- 12.2.16. Others

13. 360 Degree AnalystView

14. Appendix

14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격